DRAXIS HEALTH INC, (DRAX) Stock Research Free Stock Rating

Company Profile

Draxis Health, Inc., through its wholly owned subsidiary, operates as a pharmaceutical company. It discovers, develops, manufactures, and markets sterile products, including liquid and freeze-dried injectables and sterile ointments and creams; nonsterile products that are produced as solid oral and semisolid dosage forms; and radiopharmaceuticals, which are used for therapeutic and diagnostic molecular imaging applications. The company’s radiopharmaceutical products include BrachySeed, an Iodine-003125 brachytherapy implant, which is used for the treatment of various localized cancers; and MDP-25, a kit for the preparation of Technetium Tc99m Medronate Injection, which is used to demonstrate areas of altered osteogenesis or bone growth. Its products under development include FIBRIMAGE, a proprietary targeted molecular imaging product to aid in the diagnosis of deep vein thrombosis, is in phase III clinical trial; INFECTON for infection imaging, which is in phase II trials; and SOMATOSCAN, a preclinical stage product, which is used for imaging of neuroendocrine tumors, lymphoma, carcinoid, and small-cell lung cancer. The company has collaboration agreements with Pfizer for the development of Anipryl, which is a selegiline product for use in veterinary prescriptive applications; and GlaxoSmithKline Consumer Healthcare for the development of SpectroPhar line of dermatology products. Draxis Health was incorporated as Deprenyl Research Limited in 1987 and changed its name to DRAXIS Health, Inc. in 1994. The company is headquartered in Mississauga, Canada.

Latest Headlines

5 All-Star Stocks (at Motley Fool)

DRAXIS HEALTH INC /CN/ Financials (EDGAR Online Financials)

Friday's Winners & Losers: Nvdia (at TheStreet.com)

Friday's Health Winners & Losers (at TheStreet.com)

Friday's Biggest Stock Stars (at Motley Fool)